Mineralys Therapeutics Inc Quick Ratio (MLYS) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
MLYS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
Mineralys Therapeutics Inc 's Cash & cash equivalent grew by 497.37 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Mineralys Therapeutics Inc 's Quick Ratio to 34.87 a new company high.
Within Major Pharmaceutical Preparations industry 11 other companies have achieved higher Quick Ratio than Mineralys Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 124, from total ranking in the first quarter 2026 at 461.
Mineralys Therapeutics Secures $120 Million in Private Placement Financing, Advancing Promising Treatment for Hypertension and Chronic Kidney Disease RADNOR, Pa., Feb. 08, 2024 Mineralys Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing innovative medicines to tackle hypertension, chronic kidney disease (CKD), and other conditions driven by abnormally elevated aldosterone, has recently announced a significant milestone. The company has successfully entered into a securities purchase agreement with institutional accredited investors for a private placement financing. This financing round is expected to generate approximately $120 million in gross proceeds, which will be instrumental in further advancing Mineralys Therapeutics groundbreaking research and development efforts. Mineralys Therapeutics aims to address critical unmet medical needs by developing cutting-edge therapies that target aldosterone, an essential hormone associated with regulating blood pressure and fluid balance in the body. Abnormal elevation of aldosterone levels has been linked to hypertension, CKD, and other related diseases, presenting a significant challenge in current treatment approaches. With this private placement financing, Mineralys Therapeutics intends to accelerate the development of its promising drug candidates and propel them towards clinical trials and regulatory approval.
On the trailing twelve months basis MLYS Cash & cash equivalent more than doubled by 561.87 % in Q2 2026 year on year, while Current Liabilities grew to $19 millions, this led to increase in in Mineralys Therapeutics Inc 's Quick Ratio to 16.2, above MLYS average Quick Ratio. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Major Pharmaceutical Preparations industry 416 other companies have achieved higher Quick Ratio than Mineralys Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 3337, from total ranking during the twelve months ending first quarter 2026 at 3461.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
